The prognostic significance of POD24 in peripheral T-cell lymphoma

ABSTRACT

Background:

Peripheral T-cell lymphomas (PTCL) are an aggressive group of mature T-cell neoplasms, often associated with poor outcomes, in part, due to frequent relapsed/refractory disease. The objective of this study was to assess the prognostic impact of disease progression within 24 months (POD24) on overall survival (OS) for patients diagnosed with PTCL.

Methods:

A retrospective analysis was conducted on a cohort of patients with newly diagnosed PTCL who underwent chemotherapy at the Affiliated Hospital of Xuzhou Medical University between January 2010 and September 2021. Prognostic assessment was limited to patients who were evaluable for POD24.

Results:

Records were reviewed for 106 patients with PTCL, of whom 66 patients experienced POD24 (referred to as the POD24 group) and 40 patients did not experience POD24 (referred to as the no POD24 group). Significant differences were observed between the POD24 group and the no POD24 group in regard to clinical stage, Eastern Cooperative Oncology Group (ECOG) performance status (PS), International Prognostic Index (IPI) score, lactate dehydrogenase (LDH) levels, β2-microglobulin (β2-MG) levels, prealbumin and albumin levels. Patients in the POD24 group had a significant shorter median OS compared to the no POD24 group (11.9 months vs not reached, respectively; P < 0.001). Non response (NR) to treatment and POD24 were identified as independent negative prognostic factors for survival in patients with PTCL.

Conclusion:

POD24 is a prognostic factor associated with unfavorable outcomes in patients with PTCL and can be used to identify high-risk patients and guide treatment decisions.

KEYWORDS:

• Peripheral T-cell lymphoma
• early disease progression
• POD24
• POD12
• prognostic analysis
• Non-Hodgkin lymphoma
• clinical practice
• overall survival

Acknowledgements

We thank all the researchers and study participants for their contributions. We appreciated Dr. Rahul Bhansali (Department of Medicine, Hospital of the University of Pennsylvania) for his thorough editing spelling, grammar, and syntax.

Disclosure statement

No potential conflict of interest was reported by the author(s).

Author contributions

HC (Huimin Chen) and RM are co-first authors and contributed to the experiment conduction, data analysis and manuscript preparation. QZ, FL, YM and JZ collected the data. JC, KQ, ZY, WS, FZ, HS, DL, ZL provided the detailed information of patients. HC (Hai Cheng), KX, and WC contributed to study design and revised the manuscript. RB revised the manuscript.

Data availability statement

The dataset used during the study is available from the corresponding author on a reasonable request.

Ethics approval and informed consent

The study was approved by the ethics committee of The Affiliated Hospital of Xuzhou Medical University (XYFY2023-KL005-01). All participants signed a term of informed consent prior to study commencement.

Additional information

Funding

This study was supported by grants from Natural Science Foundation of Jiangsu Province (BK20161177, BK20221218), Scientific Research Project of the Jiangsu Provincial Health and Family Planning Commission/International (JSH-2017-008), China Postdoctoral Science Foundation project (2016M590507, 2018T110557), Xuzhou clinical Backbone Training Project (2018GG006). Suqian Key Laboratory of Hematology (M202111). Development Fund of Affiliated Hospital of Xuzhou Medical University (XYFY2021001).